NASDAQ · Biotechnology
BBIO (BBIO) Stock
$76.57
-0.03%
NASDAQ: BBIO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo
Zacks · Jul 14, 2026
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
MarketBeat · Jul 13, 2026
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Jul 10, 2026
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
Zacks · Jul 10, 2026
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
Trefis · Jul 10, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held3.92%
Institutions Held102.01%
Institutions Float Held106.17%
Peer Comparison
About BBIO
BBIO is led by CEO Neil Kumar, employs 839 people, headquartered in Palo Alto, US, publicly traded since 2019.
BBIO stock trades at $76.57 with a market capitalization of $15.00B. The stock is valued at a price-to-earnings (P/E) ratio of -22.17, price-to-book of -6.18, price-to-sales of 22.47. Over the past 52 weeks the stock has ranged between $48.78 and $93.42, and currently trades 18.0% below its 52-week high.
On profitability, BBIO generates a return on equity (ROE) of 31.67% — well above the market average, a sign of a high-quality business, return on capital employed of -166.38%, an operating margin of -113.35%, a net profit margin of -100.64%.